Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Source: SeekingAlpha
2026-05-22 07:30:00 ET
I last covered Zymeworks ( ZYME ) in April 2025, shortly after Ziihera's FDA approval. Since then, the story has shifted from initial regulatory validation toward broader zanidatamab monetization, a stronger cash position, and clearer ADC pipeline optionality. That evolution is why I am revisiting the stock now....
Read the full article on Seeking Alpha
For further details see:
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Zymeworks Inc.
NASDAQ: ZYME
ZYME Trading
-2.67% G/L:
$24.45 Last:
155,148 Volume:
$25.04 Open:
ZYME Latest News
May 14, 2026 04:05:00 pm
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
May 07, 2026 04:05:00 pm
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
ZYME Stock Data
$1,697,666,774
73,882,368
0.51%
61
N/A
Biotechnology & Life Sciences
Healthcare
CA
Middletown
